Crowdonomics
All companies
Puraclenz logo

Puraclenz

Operating

Puraclenz Holdings, Inc.

Healthcare · Technology · Old Greenwich, CT · Founded 2021

Cleans indoor air and exposed surfaces in homes and businesses at he source

Post-money valuation
$29.8M
As of Jun 2022 · from Puraclenz Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$107,011
Across 1 round since 2022
Latest share price
$8.00
Puraclenz Common Stock 1 offering price

Financials

FY2019–FY2023 · from SEC filings · hover any figure for its source
$0
−$204K
2019
$0
2020
$0
2021
$1.9M
−$1.9M
2022
$4.0M
−$1.9M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019
FY2020
FY2021
FY2022
FY2023
Income statement
Revenue
$0
$0
$0
$1,880,000
$3,996,000
Cost of goods sold
$0
$0
$0
$1,192,000
$2,696,000
Gross margin
37%
33%
Net income
-$203,954
$0
$0
-$1,887,000
-$1,877,000
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$268,991
$0
$0
$242,000
$17,000
Accounts receivable
$0
$0
$0
$162,000
$127,000
Total assets
$2,049,694
$0
$0
$2,888,000
$3,144,000
Short-term debt
$2,247,742
$0
$0
$210,000
$1,237,000
Long-term debt
$0
$0
$0
$904,000
$990,000
Total liabilities
$2,247,742
$0
$0
$1,114,000
$2,227,000
Other
Headcount
4
4
6

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$29.8M
post-money
Puraclenz Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Puraclenz Common Stock 1ClosedReg CF · Common Equity · via StartEngine
Raised $107K / $1.1MInvestors 75Post-money $29.8M

Team

9 people
Chris DooleyFounder
CEO, Director & Co-Founder

Chris Dooley leads Puraclenz operations, product development, sales, marketing, finance and manufacturing. He is also a member of the company’s board of directors. Chris is an accomplished senior executive, entrepreneur, and consultant with more than 25 years of success in SMART consumer product industries. He has held leadership positions with Marvel's toy division, Product Spring, Online Devices and iRobot. Chris led operations, U.S. sales, and marketing for iRobot’s Roomba launch and later established Roomba’s international distribution network in Europe, Canada, Russia, Korea, Japan, and Greater China. Chris is successful serial entrepreneur who has founded 5 startups, invented over 80 consumer products and 15 issued patents. Chris has a Bachelor of Science in Mechanical Engineering from Villanova University and an MBA from New York University.

Wendell MinnickFounder
Executive Chairman & Co-Founder

Wendell Minnick co-manages company operations and marketing with Chris Dooley. He also has direct responsibility for investor relations and sales. Wendell is also a member of the company's board of directors. Wendell has an extensive career as a founder, investor, and manager of early-stage companies in the energy/energy tech, materials science/nanotech, software systems, and direct consumer products industries. He has developed and commercialized advanced ceramic and nano-composite material technologies for military and commercial applications, raising more than $500 million in equity investments. His pre-seed investment in UVAIRx, Inc., enabled the advancement of photocatalytic oxidation (PCO) technology and the securing of a U.S. patent. Wendell received a bachelor’s degree in Business from Principia College and completed MBA studies in International Economics at New York University and the London School of Economics.

Christopher Dooley
CEO and Director
Ben Wilkinson
Consultant - Vice President of Digital Marketing

Ben leads brand management, e-commerce and user acquisition for Puraclenz. Ben started his career at top-tier web companies such as eBay and Overstock.com, where he directed user acquisition marketing campaigns. Ben later consulted for companies specializing in media, fintech (financial services) and e-commerce, ranging from pre-series A start-ups to public companies. Ben graduated from the David Eccles School of Business at the University of Utah with a Bachelor of Finance.

Jerrod Keith
Vice President of R&D

Jerrod Keith leads research and efficacy development of all Puraclenz products. Jerrod spent 10 years as the head of research and development for UVAIRx, Inc., where he was responsible for designing and developing all UVAIRx air purification products. He oversaw UVAIRx products from initial concept design and 3D modeling, to rapid prototyping and patent protection, to design for manufacture and assembly, to product testing. He is the inventor of Puraclenz's reaction core system for the photocatalytic purifiers patent. Jerrod earned his bachelor’s degree in Environmental Design (Architecture) from the University of Colorado Boulder.

Myorr Janha
Consultant - Vice President of Marketing Strategy

Myorr Janha leads Puraclenz's creative and strategic brand development. Myorr served as the Chief Marketing Officer of Rush Communications and Simmons Design Group. He was responsible for Global Marketing, Corporate Communications and Business Development initiatives. With over 25 years of marketing experience, Myorr successfully managed a variety of brands spanning diverse sectors in entertainment, lifestyle, and philanthropy including: Def Jam Recordings, Def Comedy Jam, Phat Farm, Rush Philanthropic Arts Foundation, Hip Hop Summit Action Network, Def Jam Interactive, Simmons Lathan Media Group and more. Myorr has a Bachelor of Business Management from St. Paul’s College.

Richard Mangi MD, MBA
Chief Medical Advisor

Richard Mangi is the chief medical advisor for Puraclenz. Richard's practice expertise includes the treatment of allergies, asthma, sinus disease, muscle and joint problems, complicated infections and travel medicine. For over twenty years Richard was Chief of Allergy, Rheumatology and Infectious Disease at the Hospital of Saint Raphael. He has also maintained a private practice in the greater New Haven area since 1974. He is a retired clinical associate professor of medicine at Yale Medical School. Richard graduated from Cornell University College of Arts and Science and S.U.N.Y. Downstate Medical Center summa cum laude. His post graduate medical training included internship and residency in internal medicine at Yale-New Haven Hospital, staff associate at the National Institutes of Health, National Cancer Institute, and fellowship at Yale Medical School. He also received an M.B.A. with honors from New York University Stern School of Business.

Cynthia Daniels
Operations Manager

Cynthia Daniels is responsible for planning, organizing, and overseeing the company’s logistics, human capital, e-commerce, and accounting processes. Cynthia comes to Puraclenz from the commercial real estate sector where she worked in cash management and finance. Cynthia received her BA in International Relations and Economics from Goucher College and completed her MA in International Affairs at The University of Chicago.

F. Wendell Minnick
Executive Chairman of the Board of Directors

Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 2 of 5 annual reports (FY2021–FY2025)

75 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-TRJan 27, 20250001665160-25-000145
    EDGAR
  • Form C-ARJun 12, 20240001099910-24-000252
    EDGAR
  • Form DMay 7, 20240001915581-24-000001
    EDGAR
  • Form DAug 12, 20220001915581-22-000001
    EDGAR
  • Form C-ARJun 8, 20220001665160-22-001781
    EDGAR
  • Form C-UJun 8, 20220001665160-22-001777
    EDGAR
  • Form C/AApr 20, 20220001665160-22-000700
    EDGAR
  • Form CMar 8, 20220001665160-22-000404
    EDGAR
Source: ManualCIK 0001915581DEShare price $8.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.